direct compression

The aim of the present work was to design controlled release tablet of Tramadol hydrochloride for prolong release and it’s in vitro evaluation. Controlled tablets of Tramadol hydrochloride comprised HPMC K15M, and HPMC K100M as the release retarding polymers. These tablets were prepared by direct compression method. The seven different formulations (F1-F7) were evaluated for pre- and post-compression parameters. In vitro dissolution studies were carried out for the optimized formulation (F7). It has found that the release of drug from the sustained release layer by 99.5% in 12 h. FT-IR studies revealed that there was no interaction between the drug and polymers used in the study. The release of Tramadol hydrochloride was found to follow a pattern of Korsmeyer-Peppas, with Quasi-Fickian diffusion. Accelerated stability studies were carried out on the prepared tablets in accordance with ICH guidelines. There were no changes observed in physicochemical properties and drug release pattern of tablets. The controlled drug release pattern was successfully achieved through the formulation of controlled tablets in this study.

The aim of present work was to design and evaluate sustained release matrix tablets of antihyperlipidemic drug. In the present investigation, polymers used in different combinations such as Eudragit RL100 and HPMC E5 in the ratio of 1:1, 1:2, 1:3 and vice versa with PVP K25 using direct compression technique were prepared. The tablets were evaluated for physical parameters like thickness, hardness, friability, weight variation, and in vitro release studies. The FTIR study indicated that the drug is stable in formulation. The maximum drug release was found to be 94.41% over a period for 12 hours for F4 batch, thus concluded that as the concentration of Eudragit RL100 is increased the drug release decreased. The drug release mechanism followed non-fickian transport from both polymer matrices. All the formulations were stored at 250C/60% RH and 450C/75% RH for 3 months. It showed that all the formulations were physically and chemically stable.

In the present study, novel co-processed superdisintegrants were developed by solvent evaporation method using crospovidone and croscarmellose sodium in the different ratios (1:1, 1:2 & 1:3) to formulate mouth dissolving tablet formulations of Meloxicam. The poor aqueous solubility of Meloxicam makes its absorption as dissolution rate-limited and thus delay onset of action. Mouth dissolving tablets of Meloxicam were prepared using the above co-processed superdisintegrants and evaluated for different parameters. Effect of co-processed superdisintegrants (such as crospovidone and sodium starch glycolate) on wetting time, disintegrating time, drug content and in-vitro release parameters have been studied. Based on in vitro dispersion time (approximately 19 sec), promising formulation CP1 was tested for in-vitro drug release pattern. Among the designed formulations, the formulation (CP1) containing 4% w/w of co-processed superdisintegrant (1:1 mixture of crospovidone and sodium starch glycolate) found as the best formulation based on drug release characteristics. From this study, it can be concluded that dissolution rate of Meloxicam could be enhanced by tablets containing co-processed superdisintegrant.